56966-61-1

Upstream product

• 3460-18-2 1,4-dibromo-2-nitrobenzene 
• 100-67-4 potassium phenolate 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 108-95-2 phenol 
• 16588-24-2 4-bromo-1-chloro-2-nitrobenzene 

Downstream Products

• 72405-05-1 (4-bromo-2-nitro-phenyl)-(2,4-dibromo-phenyl)-ether 
• 2217-56-3 bis(2,4-dinitrophenyl) ether 
• 1644527-01-4 N--(2,5-dimethoxybenzyl)-N--(2--phenoxy--5-(4,4,5,5-tetramethyl-1,3,2--dioxaborolan-2-yl)phenyl)acetamide 
• 364353-92-4 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzonitrile 
• 873977-98-1 acetic acid-[5-bromo-2-(2,4-dibromo-phenoxy)-anilide] 
• 873386-10-8 acetic acid-[4,5-dibromo-2-(4-bromo-phenoxy)-anilide] 
• 860577-30-6 acetic acid-[5-bromo-2-(4-bromo-phenoxy)-anilide] 
• 873980-49-5 4,5-dibromo-2-(4-bromo-phenoxy)-aniline 
• 72405-09-5 5-bromo-2-(2,4-dibromo-phenoxy)-aniline 
• 1041518-56-2 5-bromo-2-(4-bromo-phenoxy)-aniline 
• 909109-24-6 N-(5-bromo-2-phenoxyphenyl)-N-(2,5-dimethoxybenzyl)acetamide 
• 56966-45-1 5-bromo-2-phenoxyaniline 
• 15211-97-9 (4-bromo-2-nitro-phenyl)-(4-bromo-phenyl)-ether 

Relevant academic research and scientific papers

Enhanced copper-mediated 18F-fluorination of aryl boronic esters provides eight radiotracers for PET applications

[18F]FMTEB, [18F]FPEB, [18F]flumazenil, [18F]DAA1106, [18F]MFBG, [18F]FDOPA, [18F]FMT and [18F]FDA are prepared from the corresponding arylboronic esters and [18

N-(5-fluoro-2-phenoxyphenyl)-N-(2-[131I]iodo-5-methoxybenzyl) acetamide: A potent iodinated radioligand for the peripheral-type benzodiazepine receptor in brain

To image the peripheral-type benzodiazepine receptor (PBR) in vivo, we previously developed two positron emission tomography (PET) ligands, N-(2-[ 11C],5-dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl)acetamide ([ 11C]1a) and its [sup

Pyrrolopyrimidines as therapeutic agents

Chemical compounds having structural formula I and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatiod arthritis, disorders of the immune system, trasplant refections and imflammatory disorders.

NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS

The present invention provides compounds according to general Formula (I), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a prodrug thereof. More particularly, the present invention provides high affinity non-steroidal compounds which are agonists, partial agonists or antagonists of the progesterone receptor.